Valuation Alkem Laboratories Limited Bombay S.E.

Stocks

Market Closed - Bombay S.E. 06:02:32 2026-09-22 EDT			5-day change	1st Jan Change
5,337.15 ^INR	-0.24%		+4.87%	-3.05%

09-16	Alkem Laboratories Limited Launches Neuceno for the Treatment of Partial-Onset Seizures in Adult Patients	CI
09-15	Alkem Laboratories Limited Announces Appointment of Shubhadeep Sinha to Senior Management Position, Effective September 15, 2026	CI

Data adjusted to current consolidation scope

Fiscal Period: March	2022	2023	2024	2025	2026	2027	2028	2029
Market Cap ¹	432,909	406,055	590,890	583,680	633,575	637,461	-	-
Change	-	-6.2%	45.52%	-1.22%	8.55%	0.61%	-	-
Enterprise Value (EV) ¹	433,805	393,853	587,236	578,678	632,481	624,381	609,402	600,600
Change	-	-9.21%	49.1%	-1.46%	9.3%	-1.28%	-2.4%	-1.44%
P/E	26.3x	41.3x	32.9x	27x	27.5x	27.8x	24.2x	20.8x
PBR	5.01x	4.49x	5.73x	4.87x	4.58x	4.13x	3.65x	3.21x
PEG	-	-1x	0.4x	1.3x	4.37x	-95.34x	1.6x	1.3x
Capitalization / Revenue	4.07x	3.5x	4.66x	4.5x	4.31x	3.82x	3.43x	3.11x
EV / Revenue	4.08x	3.4x	4.64x	4.46x	4.3x	3.74x	3.28x	2.93x
EV / EBITDA	21.1x	24.5x	26.2x	23x	21x	18.2x	15.5x	13.5x
EV / EBIT	24.8x	30.3x	30.2x	26.9x	24.1x	21x	17.8x	15.4x
EV / FCF	55.4x	27.1x	33.3x	45.3x	42.8x	60.7x	29.8x	23.5x
FCF Yield	1.81%	3.69%	3%	2.21%	2.33%	1.65%	3.35%	4.25%
Dividend per Share ²	34	25	40	45	53	49.33	55.28	63.37
Rate of return	0.94%	0.74%	0.81%	0.92%	1%	0.93%	1.04%	1.19%
EPS ²	137.6	82.31	150.2	181.1	192.5	191.9	220.7	256
Distribution rate	24.7%	30.4%	26.6%	24.8%	27.5%	25.7%	25%	24.8%
Net sales ¹	106,342	115,993	126,676	129,645	147,123	166,997	185,721	204,703
EBITDA ¹	20,529	16,094	22,455	25,122	30,052	34,213	39,286	44,365
EBIT ¹	17,490	12,990	19,462	21,550	26,232	29,727	34,232	39,074
Net income ¹	16,456	9,842	17,958	21,655	23,018	23,143	27,153	31,030
Net Debt ¹	896.1	-12,202	-3,654	-5,003	-1,094	-13,079	-28,058	-36,861
Reference price ²	3,620.70	3,396.10	4,942.00	4,881.70	5,299.00	5,331.50	5,331.50	5,331.50
Nbr of stocks (in thousands)	119,565	119,565	119,565	119,565	119,565	119,565	-	-
Announcement Date	5/13/22	5/19/23	5/29/24	5/29/25	5/28/26	-	-	-

¹INR in Million²INR

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
ELI LILLY AND COMPANY	33.12x	12.04x	24.4x	0.6%	1,038B
JOHNSON & JOHNSON	29.97x	6.67x	18.66x	1.99%	649B
ABBVIE INC.	33.44x	7.83x	16.17x	2.59%	467B
ROCHE HOLDING AG	19.76x	4.83x	11.96x	2.74%	355B
NOVARTIS AG	19.95x	5.21x	12.92x	3.08%	269B
ASTRAZENECA PLC	21.41x	4.44x	12.62x	1.99%	260B
AMGEN INC.	24.9x	6.52x	11.62x	2.57%	213B
NOVO NORDISK A/S	11.64x	4.24x	8.76x	4.32%	176B
GILEAD SCIENCES, INC.	-45.54x	6.63x	25.88x	2.19%	187B
Average	16.52x	6.49x	15.89x	2.45%	401.68B
Weighted average by Cap.	23.87x	7.78x	17.95x	1.98%